Detail akcie Futura Medical online

Business Summary: Futura Medical plc is a consumer healthcare company that specializes in the development and global commercialization of sexual health products. The Company is a developer of sexual health products, including the lead product, Eroxon, and two products in development, including WSD4000 and Eroxon Intense. Eroxon is a clear gel used for the treatment of erectile dysfunction (ED) available over the counter and without prescription and addresses significant unmet needs in the ED market. Eroxon Intense provides a potential range extension of the Eroxon product and acts as an additional treatment option for men who have ED. WSD4000 is a topical treatment designed for sexual dysfunction in women. The Company has distribution partners in place in a number of major consumer markets, including Haleon in the United States, and Cooper Consumer Health in Europe.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Futura Medical PLC revenues decreased 86% to L1M. Net loss totaled L6.6M vs. income of L1M. Revenues reflect United States segment decrease of 85% to L469K, EU and UK segment decrease of 82% to L504K, Rest of the world (Region) segment decrease of 97% to L28K. Net loss reflects Development and commercialisation segment loss totaling L6.7M vs. income of L820K.